Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: HS022|DRUG: Trastuzumab|DRUG: Vinorelbine Bitartrate
Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.